Dustan Osborn, MD
Hematology & Oncology · Chehalis, WANPI 1528061132
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,115 and has fallen 97.7% since, to $70 in 2023.
Across 216 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$710
- E.r. Squibb & Sons, L.L.C.$532
- Novartis$397
- Johnson & Johnson$283
- Pharmacyclics LLC, An Abbvie Company$240
- Genentech USA, Inc.$229
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,95596%
- Education$1854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $710 |
| E.r. Squibb & Sons, L.L.C. | 29 | $532 |
| Novartis | 25 | $397 |
| Johnson & Johnson(2 entities) | 19 | $283 |
| Pharmacyclics LLC, An Abbvie Company | 17 | $240 |
| Genentech USA, Inc. | 14 | $229 |
| Rigel Pharmaceuticals, Inc. | 8 | $166 |
| Lilly USA, LLC | 8 | $165 |
| Lexicon Pharmaceuticals, Inc. | 3 | $148 |
| EMD Serono, Inc. | 8 | $129 |
| Clovis Oncology, Inc. | 6 | $105 |
| AbbVie | 6 | $101 |
| Pfizer | 6 | $84 |
| GE HealthCare | 1 | $70 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Bayer | 4 | $63 |
| Myovant Sciences Inc. | 2 | $56 |
| Taiho Oncology, Inc. | 2 | $54 |
| Sanofi | 3 | $52 |
| Seagen Inc. | 3 | $50 |
| Exelixis Inc. | 2 | $47 |
| Incyte Corporation | 2 | $41 |
| Eisai Inc. | 2 | $41 |
| Agios Pharmaceuticals, Inc. | 2 | $39 |
| Merck | 2 | $37 |
| Mylan Institutional Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $21 |
| Array Biopharma Inc | 1 | $16 |
| Amgen | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Secura Bio, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,140 in reported general payments places this provider in the 65th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Chehalis
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
- Celestia HiganoSeattle$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.